BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:Regulatory and governmental momentum is forcing change\, fast: \n\nThe Senate have recently cleared the FDA Modernization Act 3.0The FDA have developed a roadmap that’s abandoning animal testing for mAbsNIH ha ve closed the door on animal-only grantsThe UK join the plan to phase out animal testing\, announced by the Science Minster Lord Vallance\n\nMeanw hile\, your pipelines are chasing novel targets that in vivo models can't predict.\n\nThe 11th 3D Tissue Models Summit is where the industry comes to solve this. As the only industry-led forum dedicated to advancing org anoids\, organ-on-chip\, and MPS\, you'll connect with scientists from Ab bVie\, Novartis\, Vertex\, and many more who are validating these models\ , securing regulatory buy-in\, and making them work at scale. The shift i s happening\, so make sure your organization is ready.\n\nURLs:Tickets:&n bsp\;https://go.evvnt.com/3430774-2?pid=185 \;Brochure: \;https:/ /go.evvnt.com/3430774-3?pid=185 \;\n\nDate and Time: Tue\, 28 Apr 202 6 09:00 - Thu\, 30 Apr 2026 16:05\n\nVenue details: Hyatt Regency Boston\ , One Avenue de Lafayette\, Boston\, Massachusetts\, 02111\, United State s\n\n \;\n\nCategory: Conferences | Science\, Health &\; Medicine\ n\nPrices:Drug Developer Pricing - Conference + 2 Workshops: USD 4397.00\ ,Drug Developer Pricing - Conference + 1 Workshop: USD 3748.00\,Drug Deve loper Pricing - Conference Only: USD 3099.00\,Academic Pricing - Conferen ce + 2 Workshops: USD 3797.00\,Academic Pricing - Conference + 1 Workshop : USD 3248.00\,Academic Pricing - Conference Only: USD 2699.00\,Solution Provider Pricing - Conference + 2 Workshops: USD 5297.00\,Solution Provid er Pricing - Conference + 1 Workshop: USD 4548.00\,Solution Provider Pric ing - Conference Only: USD 3799.00\n\n \;\n\nSpeakers: Munzareen Khan \, Senior Scientist II\, AbbVie\, Nida Khan\, Senior Scientist\, AbbVie\, Sandeep Joshi\, Senior Scientist\, AbbVie\, Malini Iyer\, Associate Dire ctor\, AstraZeneca\, Colin Choi\, Associate Scientific Director\, Biogen\ , Christopher Hinckley\, Head\, Cellular Models and Molecular Biology\, B iogen\, Bilal Cakir\, Associate Principal Scientist\, Merck\, Stephan Kri eg\, Scientist\, Merck\, Timothy Petrie\, Principal Scientist\, Novo Nord isk\, Rachelle Prantil-Baun\, Principal Scientist\, Novo Nordisk\, Bindu Sukumaran\, Senior Principal Scientist\, Novartis\, Gizem Rizki\, Senior Principal Scientist\, Novartis\, Regis Doyonnas\, Senior Principal Scient ist and Associate Fellow - Research\, Pfizer\, Elham Malekzadeh\, Senior Scientist\, Takeda\, Jason Ekert\, Head\, Neuromuscular Focus Area and Tr anslational Biology\, UCB\, Clara Morral Martinez\, Research Investigator \, Incyte Corporation\, Hailey Cambra\, Gene Editing Research Scientist\, Vertex Pharmaceuticals\, Graham Marsh\, Scientific Director Critical\, P ath Institute\, Megan LaFollette\, Executive Director\, The 3R Collaborat ive\n DTEND:20260430T160500 DTSTAMP:20260512T214302Z DTSTART:20260428T090000 LOCATION:Hyatt Regency Boston\, One Avenue de Lafayette\, Boston\, Massach usetts\, 02111\, SEQUENCE:0 SUMMARY:Regulatory and governmental momentum is forcing change\, fast:\nTh e Senate have recently cleared the FDA Modernization Act 3.0The FDA have developed... UID:93d99409-cd7c-4063-889d-0d2e89373806 END:VEVENT END:VCALENDAR